- Home
- SGC vs CLLS Comparison
SGC vs CLLS Comparison
Compare SGC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | CLLS |
|---|---|---|
| Founded | 1920 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 384.3M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SGC | CLLS |
|---|---|---|
| Price | $10.01 | $3.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.00 | $8.50 |
| AVG Volume (30 Days) | 35.2K | ★ 43.6K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $4.04 | $40.37 |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $22.00 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $1.10 |
| 52 Week High | $13.78 | $5.48 |
Technical Indicators
Market Signals| Indicator | SGC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 40.31 |
| Support Level | $9.72 | $3.41 |
| Resistance Level | $10.49 | $3.77 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 20.09 | 11.98 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.